SUNFISH Part 2: 24-month Efficacy and Safety of Risdiplam in Patients with Type 2 or Non-ambulant Type 3 Spinal Muscular Atrophy (SMA) Oskoui, M., Day, J. W., Deconinck, N., Mazzone, E., Nascimento, A., Saito, K., Vuillerot, C., Baranello, G., Bloespflug-Tanguy, O., Goemans, N., Kirschner, J., Kostera-Pruszczyk, A., Servais, L., Gerber, M., Gorni, K., Kletzl, H., Martin, C., Scalco, R. S., Staunton, H., Yeung, W., Mercuri, E. LIPPINCOTT WILLIAMS & WILKINS. 2021

View details for Web of Science ID 000729283602038